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A CD146 FACS Protocol Enriches 
for Luminal Keratin 14/19 Double 
Positive Human Breast Progenitors
Ólöf Gerdur Ísberg1,2, Jiyoung Kim1, Agla J. Fridriksdottir1, Mikkel Morsing1,3, 
Vera Timmermans-Wielenga4, Lone Rønnov-Jessen5, Ole W. Petersen1 & René Villadsen  1
Human breast cancer is believed to arise in luminal progenitors within the normal breast. A subset 
of these are double positive (DP) for basal and luminal keratins and localizes to a putative stem cell 
zone within ducts. We here present a new protocol based on a combination of CD146 with CD117 
and CD326 which provides an up to thirty fold enrichment of the DP cells. We show by expression 
profiling, colony formation, and morphogenesis that CD146high/CD117high/CD326high DP cells belong to 
a luminal progenitor compartment. While these DP cells are located quite uniformly in ducts, with age 
a variant type of DP (vDP) cells, which is mainly CD146-negative, accumulates in lobules. Intriguingly, 
in specimens with BRCA1 mutations known to predispose for cancer, higher frequencies of lobular vDP 
cells are observed. We propose that vDP cells are strong candidates for tracing the cellular origin of 
breast cancer.
Once fully developed, the breast belongs to a category of tissues and organs with relatively little cellular turnover. 
The breast epithelium contains two major lineages, and by far the majority of mitotic activity, when present, 
takes place within the luminal epithelial lineage1. This may explain why most breast cancers are caricatures of the 
cellular phenotypes found herein. We have previously investigated two major luminal cellular phenotypes in the 
human breast gland: Estrogen receptor α-positive (ERα+) cells and keratin 14-positive (K14+) cells of which the 
latter also express luminal-specific keratins (hereafter referred to as double positive, DP cells)2–5. Interestingly, 
similar phenotypes are found within the two most frequent subtypes of human breast cancer – the luminal sub-
type and basal-like subtype, respectively6. While we have devised a protocol for the prospective isolation and cul-
ture of the ERα+ 2, studying pure populations of DP cells has so far had to rely heavily on cloning of cultured cells 
with no or little prior enrichment4,5. However, assays based on collecting ducts and lobules under the microscope 
have strongly suggested that DP cells are indeed progenitors originating primarily from within a ductal stem cell 
zone4. Others have described DP cells as primarily a lobular characteristic7,8. In fact, there is increasing evidence 
for the existence of both ductal and lobular progenitor cells with different marker expression and differentia-
tion potential8–11. The exact characterization of luminal progenitors has been complicated by the fact that these 
populations seem to be highly variable among individuals10. For instance, both the number and the distribution 
of progenitor cells appear to change with donor age or number of generations in culture9,12. In culture, we have 
previously enriched partially for DP cells based on CD117 and others have confirmed the progenitor properties 
of such populations12,13. However, CD117 is widely expressed in the luminal compartment of the adult breast2,14. 
Here, we enrich for DP cells by inclusion of CD146 in a FACS protocol and further show that the appearance of a 
CD146neg, variant DP (vDP) cell correlates with higher age and predisposition to cancer.
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Results
DP and CD146-positive cells accumulate in ducts of the human normal breast gland. We 
and others have previously demonstrated the presence of a stem cell zone rich in DP- or Aldehyde dehydroge-
nase-positive (ALDH+)  cells in the ducts of the human breast4,15. Here, based on immunohistochemistry and 
quantification of stained ductal and lobular profiles, in a sample of 40 human normal breast biopsies, we confirm 
a topographical accumulation of DP cells in ducts (Fig. 1A, Supplementary Fig. S1, Supplementary Tables S1 
and S2). By applying candidates from our antibody repository16 in search for surface markers other than CD117 
eligible for prospective isolation of DP cells we came across CD146, also referred to as melanoma cell adhesion 
molecule (MCAM). While CD146 in general is more widespread in stromal- and myoepithelial cells, in the lumi-
nal compartment, unlike CD117, CD146 is restricted mainly to the ducts (Fig. 1B, Supplementary Tables S3 and 
S4). Therefore, CD146 seemed promising as a more specific marker of DP cells than CD117.
A CD146high/CD117high/CD326high FACS protocol enriches for DP cells. With the aim of enriching 
for DP cells we included CD146 in a previously described protocol used by us and others2,4,17,18 for isolation of 
CD326high luminal cells and further stratified the cells according to CD117 expression (Fig. 2A). Thus, three 
subpopulations were sorted as CD146high/CD117high/CD326high, CD146low/CD117high/CD326high, and CD146low/
CD117low/CD326high, in the following referred to as CD146high/CD117high¸ CD146low/CD117high and CD146low/
CD117low, respectively. The luminal identity of these cells was confirmed by the absence of α-smooth muscle actin 
Figure 1. DP and CD146+ luminal cells accumulate in ducts of the human normal breast gland. (A) Dot plot 
comparing the proportion of structures containing DP cells shows that on average DP cells are more frequent 
in ducts. Image inserts show examples of DP cells marked by arrows in a lobule (left) and a duct (right) after 
immunoperoxidase stain. *p < 0.0001 tested by Mann-Whitney test (n = 40 biopsies, listed in Supplementary 
Table S1). Bar, 50 µm. (B) Representative immunoperoxidase stainings in serial sections demonstrating that 
CD146+ luminal cells are preferably present in ductal structures (upper panel), whereas CD117+ cells are 
generally present in both lobules and ducts (lower panel). Arrowheads mark examples of CD146+ cells in the 
luminal compartment. Bar, 50 µm.
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(α-sm actin) and the presence of luminal keratin 7/8 in stainings of cellular smears (Fig. 2B). When comparing 
sorted luminal subpopulations with respect to the presence of DP cells in terms of K19/K14 double positivity the 
CD146high/CD117high gate consistently came out as the one with the highest frequency of DP cells (Fig. 2C). The 
CD146high/CD117high gate typically comprised 10% of the total CD326high luminal population (ranging from 5 to 
Figure 2. A CD146high/CD117high/CD326high FACS protocol enriches for DP cells. (A) FACS diagrams showing 
uncultured primary cells gated into luminal CD326high cells (left diagram, right frame) from which CD146high/
CD117high, CD146low/CD117high and CD146low/CD117low populations were selected (right diagram). (B) 
Smears of sorted CD146high/CD117high, CD146low/CD117high, CD146low/CD117low, basal and stromal cells 
immunostained for α-sm actin and K7/8. Bar, 50 µm. The low frequencies of α-sm actin-positive cells in the 
luminal subpopulations are indicative of few, if any, contaminating basal cells. (C) Bar graph of the relative 
number of DP cells in FACS sorted populations showing a higher frequency of K14+/K19+ DP cells from the 
CD146high/CD117high gate (black bars) compared to CD146low/CD117high (grey bars) and CD146low/CD117low 
cells (white bars) (p < 0.05 tested by ANOVA with Tukey HSD test, n = 4 biopsies). The frequency of CD146low/
CD117high DP cells was set at an arbitrary level of 100.
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Figure 3. Characterization of CD146high/CD117high cells. (A) Heatmap of selected DEGs in three luminal 
populations isolated by FACS. Genes are sorted according to lineage into basal, luminal progenitor and 
mature luminal markers. The RNA-Seq data demonstrate that the CD146high/CD117high population differs 
from CD146low/CD117high cells by a higher expression of basal markers, while CD146low/CD117low cells have 
increased expression of mature luminal markers. Log2-scaled expression values are presented for each gene, 
and the color key indicate the Z-score (n = 3 biopsies). (B) Functional progenitor assays demonstrate that 
CD146high/CD117high cells generally exhibit the highest level of activity. (a) In a colony forming unit (CFU) 
assay significantly more colonies were generated from CD146high/CD117high cells compared to the other two 
populations (n = 4 biopsies). (b) In a mammosphere assay CD146high/CD117high cells generated significantly 
more spheres than the other two populations (n = 3 biopsies). (c) In a 3D morphogenesis assay only CD146high/
CD117high cells developed significantly more branching structures than CD146low/CD117low cells (n = 4 
biopsies). (d) In a branching morphogenesis assay on fibroblast feeders only CD146high/CD117high cells formed 
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15%, data not shown). In summary, these results show that isolating a CD326high luminal CD146high/CD117high 
population enriches for DP cells.
Characterization of CD146high/CD117high cells. To compare CD146high/CD117high cells with CD146low/
CD117highand CD146low/CD117low cells RNA sequencing (RNA-Seq) analysis was performed (Supplementary 
Tables S5 and S6) and differentially expressed genes (DEGs) among the three subpopulations were established 
by the NOISeq method (Supplementary Table S7). As revealed in a heatmap of selected DEGs, the CD146high/
CD117high cells expressed a number of basal/myoepithelial markers in addition to typical markers of progenitor 
cells (Fig. 3A). In this respect, it is worthwhile to emphasize that this expression concerns RNA only and not 
detectable protein. Thus, we have no reason to believe that it reflects contamination with myoepithelial cells per 
se. Rather, it may relate to what others have found in mice of some transient hybrid multipotent progenitors coex-
pressing basal and luminal markers19. Both CD146high/CD117high as well as CD146low/CD117high cells expressed 
relatively high levels of several luminal progenitor markers, including KIT and TNFRSF11A/RANK that have 
been correlated to progenitors accumulating in preneoplastic breast tissue of BRCA1 mutation carriers20,21. By 
contrast, the CD146low/CD117low cells remained mature luminal-like with higher levels of, for instance, ALCAM 
and ESR1/ERα (Fig. 3A). Application of gene ontology (GO) analysis as well as computerized pathway enrich-
ment analysis using Kyoto encyclopedia of genes and genomes (KEGG) database further revealed cytoskeletal 
components and pathways of focal adhesions as most significantly different between CD146high/CD117high and 
CD146low/CD117high populations (Supplementary Table S8 and Supplementary Fig. S2).
To functionally assess the progenitor potential of the three sorted luminal subpopulations we analyzed their per-
formance in the following assays: a colony forming unit (CFU) assay, a mammosphere assay and a three dimensional 
(3D) morphogenesis assay, which have all been implemented previously by us and others to analyze progenitor 
activity of breast epithelial cells4,5,22,23. In addition, we included a two dimensional (2D) feeder based morphogenesis 
assay which allows for analysis of branching structures upon epithelial-stromal interaction24. Based on these assays, 
the CD146high/CD117high cells demonstrated the highest progenitor potential (Figs 3B and S3).
In order to further characterize the luminal CD146high/CD117high profile in situ, we performed multicolor 
immunohistochemistry that demonstrates correlation between CD146 and a number of putative progenitor 
markers in ductal structures (Fig. 4). As expected CD146-positive cells could be found to coexpress CD117 or 
K14. Furthermore, markers we previously described as being present in ductal stem cell zones, including SSEA4 
as well as keratins 5, 15 and 174, were co-expressed with CD146 in cells of the luminal compartment. By contrast, 
CD146 was generally not present in cells that were positive for mature luminal marker Ks20.82.
Based on these findings, we conclude that inclusion of CD146 contributes a significant improvement over that 
of CD117/CD326 or CD326 only in attempts to prospectively isolate human breast DP cells with a progenitor 
profile.
Variant DP cells accumulate in lobules with age and in tissue from BRCA1 mutation carriers. 
We have previously reported that in culture the number of DP cells increases with the number of population dou-
blings12. This prompted us to test whether the frequency of DP cells also in situ increases with age. Indeed, based 
on multicolor imaging of smears directly from biopsies we found an increase in relative frequency of DP cells with 
age (n = 20 samples, Fig. 5A and Supplementary Table S9). Keeping in mind that DP cells are already present in 
relatively high numbers in the ducts, it was not surprising that the age-related increase in DP numbers manifested 
itself in the lobules when comparing “young” (here defined as <29 years old with 2.9% lobules containing DP 
cells) and “old” (>29 years with 20.5% lobules containing DP cells) women (Fig. 5B). To analyze whether DP cells 
in lobules differ from DP cells in ducts we investigated a number of biopsies by immunofluorescent staining. As 
it turned out lobular DP cells were mostly CD146neg, and thus referred to here as variant DP (vDP cells) (Fig. 5C 
and Supplementary Table S10). This led us to speculate on a possible pathophysiological role of vDP cells in 
breast cancer evolution which is after all an age-related disease. To get a preliminary impression of this we exam-
ined a sample of breast tissue specimens from women with known mutations in the BRCA1 gene and another 
sample of basal-like breast cancers with the majority of the neoplastic cells being DP. As the normal-derived 
samples from BRCA1 mutation carriers were completely anonymously donated, we could not make an exact 
age-matching of this material to that from presumed non-carriers. However, there is no reason to believe that 
the BRCA1-affected women were particularly old when undergoing mastectomy of the breast21. Irrespective of 
age, the tissue samples from BRCA1 mutation carriers were characterized by having significantly more DP cells 
(40.5% lobules containing DP cells) (Fig. 5B). Furthermore, these were more active in terms of cell cycling (Fig. 6 
and Supplementary Table S11). Both lobular DP cells from BRCA1 mutation carriers and cancer associated DP 
were generally CD146neg and as such similar to age related lobular vDP cells (Supplementary Tables S10 and S12).
Collectively, we conclude that CD146high/CD117high/CD326high progenitors represent what could be referred 
to as the default luminal progenitor in the human breast and that additional vDP cells arise with age and under 
pathological conditions, suggesting that vDP cells represent precursor cells and their descendants in tissues pre-
disposed to cancer development as well as in overt cancer.
significantly more branching structures than CD146low/CD117low cells (n = 3 biopsies). *p < 0.05, **p < 0.005, 
***p < 0.0005, and ****p < 0.00005, tested by ANCOVA with Tukey’s HSD test. Each scatter dot plot is lined at 
median with interquartile range.
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Discussion
In this study we present a novel protocol for enrichment of luminal progenitors harboring DP cells and pro-
vide evidence for their progenitor status. The preferential location of these progenitors within ductal zones is in 
line with our previous observation based on culturing cells from microcollected breast gland structures4. Apart 
from demonstrating an increased level of activity in culture-based progenitor assays, the CD146high/CD117high/
CD326high cells have a unique expression profile showing an increased level of basal/myoepithelial markers. This 
profile is reminiscent of the transient hybrid population that has been described during early development of the 
mouse mammary gland19, suggesting that the CD146high/CD117high/CD326high compartment harbors an early 
luminal progenitor close to the apex of hierarchical differentiation tree. In support of this, others have recently 
published a study including single cell RNA profiling to evaluate the heterogeneity of ALDH+ luminal progen-
itors, in which the cluster with the highest levels of canonical markers of breast stemness also expressed high 
levels of CD14610. Both CD146high/CD117high and CD146low/CD117high cells express higher levels of several lumi-
nal progenitor markers compared to CD146low/CD117low luminal cells, including TNFRSF11A/RANK. As with 
Figure 4. CD146high luminal cells express with a number of progenitor markers. Immunofluorescent double 
stainings of CD146 (green) along with putative progenitor markers CD117, K14, SSEA4, K15, K5, K17 as well as 
K19 and Ks20.8 (all in red) in normal breast tissue sections. Nuclei are stained with DAPI (blue). Image subsets 
are shown in single color channels, and arrowheads mark examples of co-stained cells. While CD146high cells 
co-express progenitor markers and K19, CD146high and Ks20.8+ cells are generally confined to separate luminal 
compartments. Bar, 50 µm. Image subsets, bar, 20 µm.
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KIT/CD117 increased expression of RANK has been implicated with aberrant accumulation in preneoplastic 
breast epithelium of BRCA1 mutation carriers, which in turn suggests that such cells could be a target for breast 
carcinogenesis20,21.
The age-related increase of DP cells reported here concurs with an earlier study in which culture based assays 
demonstrate age-dependent expansion of DP cells12. That DP cells tend to accumulate with age, and are more 
frequently present in lobular structures in women ≥29 years of age may be of significance with regard to car-
cinogenesis since the majority of breast cancers arises within terminal ductal lobular units25. Furthermore, the 
presence of CD146neg or CD146lowvDP cells in lobules implies that this population could be a different entity than 
its ductal counterpart expressing CD146. Recent data provided by our laboratory suggest that ducts and lobules 
do in fact contain basal stem cells or progenitors with different properties which may impact on the progeny at the 
Figure 5. Variant DP cells accumulate in lobules with age and in tissue from BRCA1 mutation carriers.  
(A) Immunofluorescent staining of crude smears with K14 (green), K19 (red) and nuclei (blue) (left image). 
Arrowheads mark DP cells. Bar, 20 µm. A positive correlation was found between age and the frequency of DP 
cells (right), analyzed by Spearman rank test (rho = 0.57, p < 0.01). (B) Dot plots of the proportion of lobular 
structures with DP cells in women <29 years (average age: 19.7 years, median: 19), ≥29 years (average age: 44.4 
years, median: 43) and BRCA1 mutation carriers (information about donor age not available). The age-selected 
data for lobules are derived from Supplementary Table S1, which are also included in Fig. 1A. The proportion 
of lobules containing DP cells is significantly higher in the older age group (20.5%) and in women with BRCA1 
mutations (40.5%) as compared to the younger age group (2.9%). *p < 0.05, **p < 0.005, and ****p < 0.000005 
using ANOVA with Tukey’s HSD test. Each scatter dot plot is lined at median with interquartile range (<29 
years: n = 18, ≥29 years: n = 22, BRCA1 mutated: n = 8). (C) Immunofluorescent staining demonstrating a 
segregation of DP and CD146+ cells in a lobule (left image) compared to a duct (right image) with CD146-
expressing DP cells. K14 is shown in green, CD146 in red and nuclei in blue. Image subsets are shown in single 
color channels. Arrows indicate DP cells that are CD146neg while arrowheads point to CD146+ DP cells. Bars, 
25 µm.
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respective anatomical regions9. Intriguingly, the vDP-like phenotype observed here in selected basal-like tumors 
is not incompatible with their origin in lobules.
BRCA1 mutation carriers have a profound increased lifetime breast cancer risk26. Lim et al. reported that the 
breast glands of BRCA1 mutation carriers have increased numbers of luminal progenitors, suggesting that this 
population contains the cell of origin for subsequent tumor formation20. While here we cannot correlate the data 
of the BRCA sample with age, indeed, irrespective of age, the frequency of DP cells is higher among BRCA1 muta-
tion carriers. DP cells of BRCA1 mutation carriers are also more frequently cycling compared to non-carriers as 
demonstrated by Ki67 staining, which supports that these women may host luminal progenitors at an aberrant 
frequency. An increased proliferative state could also imply an increased risk of accumulating transforming muta-
tions in these cells. Furthermore, just as is generally the case for sporadic basal-like tumors, breast carcinomas 
derived from BRCA1 mutation carriers are more proliferative when compared to ERα+ tumors27,28.
In conclusion, we suggest that the luminal progenitor compartment containing DP cells is key for understand-
ing the cellular origin of breast cancer.
Materials and Methods
Human breast tissue samples. Normal breast biopsies were acquired from healthy women undergoing 
reduction mammoplasty for cosmetic reasons at Capio CFR Hospitaler, Lyngby or Hellerup, Denmark. All donors 
were informed before surgery and agreed by written consent to donate tissue. The specimen donor’s personal 
information was confidential and protected except the date and year of birth. In some cases only the year of birth 
was available. Material from some of the biopsies have been used previously in several studies2,9,16; however, 
picking the sample material was done randomly and all relevant tissue processing were done specifically for this 
study which has not been previously published. Normal breast tissue specimens from BRCA1 mutation carriers as 
well as breast carcinomas were obtained completely anonymously from patients at the State University Hospital, 
Copenhagen. The storage and use of human material has been reviewed and approved by the Regional Scientific 
Ethical Committees (H-2-2011-052 and H-3-2010-095) and the Danish Data Protection Agency (2011-41-6722) 
and has been handled according to established guidelines in subsequent experiments. In total, normal-derived 
samples from 80 women were included of which 10 were known BRCA1 mutation carriers. Of the biopsies that 
were used for flow cytometry four were immunostained, three biopsies were submitted to RNA expression profil-
ing and nine biopsies were included in cell culture assays. 23 ERα-negative breast carcinomas were selected from 
a sample material of 150 invasive breast carcinomas.
Immunostaining. Immunosmears: The 20 biopsies included for staining of crude smears were picked ran-
domly among material used for other routine analyses in the lab. Isolation of breast epithelial organoids was 
performed as previously described29. Primary epithelial organoids were dissociated into single cells with 0.25% 
trypsin and 1 mmol/L EDTA. Cells were suspended in PBS with 10% goat serum, dripped onto glass slides with 
a pipette and air dried before fixation in either ice cold methanol for 5 minutes or in 3.7% formaldehyde (Merck, 
Darmstadt, Germany) followed by permeabilization with Triton X-100 detergent (Sigma-Aldrich). Smears 
were incubated with primary antibodies for at least 2 hours before incubation with isotype-specific secondary 
fluorescent antibodies for 30 minutes (Supplementary Table S13). Double positive (DP) cells were detected by 
co-expression of K14/K19. Additionally, crude smears from some biopsies were also analyzed by co-expression of 
K14/K7/8 (using CAM5.2 that detects keratins 7 and 830). K7 is more widely expressed in the luminal compart-
ment compared to K199. Cells sorted by FACS were spun down, dripped onto glass slides and fixed as described 
above. Quantification of DP cells among sorted cells was done by quantifying 3 × 100 cells for each population 
(n = 4 biopsies). Analysis of the presence of basal cells and luminal cells in sorted cells was performed with 
Figure 6. DP cells are more frequently cycling in tissue from BRCA1 mutation carriers. (A) Normal tissue 
from a woman with known BRCA1 mutation immunostained for K14 (green), cell cycle marker Ki67 (blue) 
and luminal keratin marker CAM5.2 (red). Arrowhead marks a Ki67+ DP cell. Bar, 25 µm. Lower panel image 
subsets are shown in single color channels, including DAPI nuclear stain (white). Bar: 10 µm. (B) Dot plot 
comparing the proportion of Ki67+ cells in the DP population between women with BRCA1 mutations and 
women with no known mutations. *p < 0.017 (normal: n = 7; BRCA1 mutated: n = 7) by Mann Whitney test.
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staining for α-sm actin and CAM5.2, respectively. For each population 3 × 100 cells were quantified. Nuclei were 
stained with DAPI (Life Technologies, Thermo Fisher Scientific). Immunohistochemistry: Snap frozen tissue spec-
imens were cut at 6 µm on a cryostat (Microm HM560, Axlab, Denmark) and were subsequently fixed either in 
methanol or formaldehyde as described for immunosmears. For peroxidase stainings, Ultravision ONE Detection 
System was utilized according to the manufacturer’s instructions (Labvision, Thermo Fisher Scientific). Nuclei 
were stained with hematoxylin. For immunofluorescence the specimens were incubated for 2 hours with primary 
antibody followed by incubation with secondary isotype-specific Alexa Fluor antibodies, as described for stain-
ings of smears. Nuclei were stained with DAPI. Antibodies and dilutions are listed in Supplementary Table S13.
Microscopy. Routine analysis of brightfield and fluorescent samples were performed on a Leica DM550B 
microscope. Peroxidase images were acquired using this microscope equipped with a DFC550 digital camera 
(Leica). Fluorescent images presented in the figures were acquired using a confocal microscope (Zeiss LSM 700) 
located at the Core Facility for Integrated Microscopy, Faculty of Health and Medical Sciences, University of 
Copenhagen. Phase contrast images were acquired using a Leica DM IL equipped with a MC170 HD digital 
camera. For image acquisition at low magnification a Leica MDG41 equipped with a MC170 HD digital camera 
was used.
Quantification and statistical analysis. Quantification of the frequency of structures containing lumi-
nal K14+ cells were done under the microscope based on sections stained by immunoperoxidase. A lobule or 
duct with one or more positive cells present was scored as positive. Evaluation of the distribution of CD146- and 
CD117-expressing luminal cells were performed on serial sections stained by immunoperoxidase. Quantification 
of the frequency of K14/K19 and K14/K7/8 DP cells on smears were performed either directly under the micro-
scope utilizing filters that visualize Alexa Fluor 488, Alexa Fluor 568 or both simultaneously or on images that 
were acquired and digitally stored. Quantification of the frequency of K14/K7/8 DP cells in ducts and lobules 
(Table S2) were performed on digitally stored images. In both cases areas of interest was located based on nuclear 
DAPI stain to avoid any bias in selection. A TDLU consists of the most distal part of the ductal-lobular system 
and include the collection of lobular ductules/acini branching from the intralobular terminal duct, as well as 
the connecting extralobular terminal duct31 (Fig. S1). For evaluation and quantification of DP cells in lobules, 
intralobular ducts were regarded as a ductal segment to distinguish between ductules/acini and the correspond-
ing duct when visually distinguishable – either by histology or by the presence of distinct K14+/K7/8− basal cells. 
Quantification of the proportion of DP cells expressing Ki67 was done using a confocal microscope by first assess-
ing the number DP cells in a structure before evaluating Ki67 expression by image acquisition (Supplementary 
Table S11). Generally, several sections from a biopsy sample were evaluated. All statistical analyses were per-
formed using the computing program R (Version 3.5.1) and graphs were drawn either in R or the graphic pad 
Prism (version 8.0) and mentioned in figure- and table legends where statistics was used. In Denmark the average 
age of primiparous women is 29 years (Danmarks Statistik 2017, www.statistikbanken.dk/FOD11), which was 
used to divide women into two age-groups (Fig. 5B).
FACS. Primary breast organoids were dissociated into single cells as described for immunosmears. Viable cell 
suspensions were filtered through a 100 µm filter and resuspended in HEPES buffer supplemented with 0.5% BSA 
(bovine fraction V; Sigma-Aldrich) and 2 mM EDTA, and incubated for 30 min at 4 °C with antibodies CD146 
(1:20, clone P1H12, Alexa Fluor (AF) 647 conjugate, BD Biosciences), CD117 (1:20, clone 104D2, PE conjugate, 
BD Biosciences) and CD326 (1:20, clone 9C4, AF488 conjugate, BioLegend) (See Supplementary Table S13). 
Controls were incubated without antibodies and in selected experiments as Fluorescence Minus One (FMO) con-
trols omitting CD146 antibody. Following incubation the cells were washed twice in HEPES/BSA/EDTA buffer 
and filtered through a 10 or 20 µm filter cup (Filcons). For dead cell discrimination, 1 µg/mL propidium iodide 
(Invitrogen) was added prior to analysis in a flow cytometer (FACSAria II or FACSFusion, BD Biosciences). 
When sorting into 96 well plates the instrument’s automated cell deposition unit (ACDU) and single cell sorting 
parameters were utilized.
RNA-Sequencing. Total RNA from CD146high/CD117high, CD146low/CD117high and CD146low/CD117low 
CD326high luminal cells sorted from three different biopsies was isolated using 500 µL TRIzol® (Invitrogen) and 
a spin-column method (Zymo research). Library construction, sequencing process and the data analysis were 
conducted by Beijing Genomics Institute, as described previously9. In short, cDNA library of the enriched mRNA 
was fragmented into 200 bps and sequencing adaptors were ligated and amplified before quality control with a 
Agilient 2100 bioanalyzer. The libraries were sequenced on a HiSeq2000 sequencer (Illumina), 50 bp high output 
to average depth of 10 million reads. The summary of RNASeq data is included in Supplementary Table S5 and a 
detailed list of genes in Supplementary Table S6. Readout alignment was performed by SOAP (version 2.21) and 
gene expression was quantified by RPKM algorithm. Differently expressed genes among groups were identified 
by the NOISeq method using a cutoff value as fold difference higher than 2 between two groups with probability 
higher than 0.832. The selection of basal-, luminal progenitor- and mature luminal markers shown in the heatmap 
in Fig. 3A was based on previously published expression data2,20,33. GO and KEGG databases were used for gene 
ontology enrichment analysis and pathway enrichment analysis, respectively.
Cell culture. All cell cultures were incubated in a humidified incubation chamber in 5% CO2 at 37 °C.
CFU assay: Each of the CD146high/CD117high, CD146low/CD117high and CD146low/CD117low subpopulations were 
sorted directly into a 96 well plate precoated with collagen I (Corning) as 10 cells per well in the presence of 100 µL 
FAD2 medium (DMEM, high glucose, no calcium (Life Technologies) 3:1 v/v with 2 mM glutamine, 0.5 µg/mL 
hydrocortisone (Sigma-Aldrich), 5 µg/mL insulin (Sigma-Aldrich), 10 ng/mL cholera toxin (Sigma-Aldrich), 10 ng/
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mL EGF (Peprotech), 1.8 × 10−4 M adenine, 10 µM Y-27632 (Y0503, Sigma-Aldrich) and 5% FCS (Sigma-Aldrich)) 
as described in2. Cultures were monitored for 14 days before fixation and hematoxylin staining. Proliferating 
clonal islets were determined under a microscope as colonies consisting of more than 25 cells. The sample mate-
rial was derived from four different biopsies. Mammosphere assay: Sorted cells were counted and plated in tripli-
cates in ultra-low attachment 24-well plates (Costar) with 5,000 cells/well in mammary epithelial growth medium 
(MEGM, MEBM (Lonza) supplemented with 2% B27 (Invitrogen), 20 ng/mL EGF (Peprotech), 20 ng/mL bFGF 
(Peprotech), and 4 µg/mL heparin (Sigma)). Cultures were monitored for 14 days before final evaluation was 
performed by counting mammospheres ≥80 µm in diameter. The sample material was derived from three dif-
ferent biopsies. 3D morphogenesis assay: Sorted cells were counted and 20,000 cells per well were embedded in 
triplicates in 300 µL Matrigel (BD Biosciences) on top of a primary epithelial feeder overlayed by 250 µL Matrigel 
in 24 well plates. The cells were cultured in F12 medium (Ham’s F12 (Invitrogen) supplemented with 2 mM glu-
tamine, 5 µg/mL insulin, 1 µg/mL hydrocortisone, 0.1 µg/mL cholera toxin, 10 ng/mL EGF and 5% FCS). After 21 
days branching structures were quantified under a phase contrast microscope. The sample material was derived 
from four different biopsies. Branching morphogenesis assay with epithelial-stromal interaction: Sorted cells 
were seeded in triplicates of 5,000 cells on confluent human CD105high/CD26low fibroblast feeders in T12.5 cul-
ture flasks. This co-culture condition was previously established with modified breastoid base medium without 
HEPES (DMEM/F-12, 1:1), 1 μg/mL hydrocortisone (Sigma-Aldrich), 9 μg/mL insulin (Sigma-Aldrich), 5 μg/
mL transferrin (Sigma-Aldrich), 5.2 ng/mL Na-Selenite (BD Industries), 100 μM ethanolamine (Sigma-Aldrich), 
20 ng/mL bFGF, 5 nM amphiregulin (R&D Systems), with the addition of 10 μM Y-27632 (Axon Medchem), 
1.8 × 10−4 M adenine (Sigma Aldrich) and the serum replacement B27 (20 μL/mL, Life Technologies)24. After 14 
days cultures were fixed and stained for K19 by immunoperoxidase. After image acquisition stained epithelial 
structures were analyzed and quantified (ImageJ version 1.49 t) as described previously24. Briefly, epithelial struc-
tures were segmented followed by analysis of the number of structures and the total area using the plugin Analyse 
Particles. The sample material was derived from three different biopsies.
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